Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022.
The panel has advised manufacturers to develop modified vaccines that add an omicron BA.4/5 spike protein component to the vaccine composition to create a two-component (bivalent) booster vaccine.
Genmab Plans To File US Application For Epcoritamab In Blood Cancer Setting
Genmab...
Login or create a forever free account to read this news
Sign up/Log in